Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-992: Pembrolizumab plus chemoradiotherapy vs chemoradiotherapy alone in muscle-invasive bladder cancer
2023-503500-87-00Phase 4Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 4, randomised, double-blind trial in muscle-invasive bladder cancer (MIBC) comparing Pembrolizumab plus chemoradiotherapy with Placebo plus chemoradiotherapy (2 arms). Primary endpoint: Bladder Intact Event-Free Survival. Planned start Mar 2020; status: authorised.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2023-503500-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503500-87-00.